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                                         INTRODUCTION
          Bell's palsy is the most frequent disease of the seventh cranial nerve, with a 
good prognosis. More than 70% patients attain complete clinical recovery, with no 
noticeable residua 1. Persistent sequellaes are usually noted in cases with profound 
axonal loss only. Electrophysiological tests may offer valuable information in 
defining the severity of nerve injury and a possible residual dysfunction 2. 
Treatment of Bell’s palsy is still controversial. Therapy is difficult to evaluate, 
because as many as two thirds of patients with Bell’s palsy spontaneously recover 
and achieve near-normal function. Many patients begin to improve as early as 10 
days after the onset, even without treatment 3. Drug therapy mainly consists of 
corticosteroids with or without an antiviral (acyclovir). These drugs hasten the 
recovery and lessen the ultimate degree of dysfunction. 
        One hundred and one patients  with clinical  signs of Bell's  palsy were 
included in this study. Clinical signs were recorded (the degree of facial muscle 
palsy)  and  treated  with  steroids  and  acyclovir  in  combination  or  separately. 
Electrophysiological  tests  (amplitude  and  latency  of  compound  muscle  action 
potential CMAP) were done on first week and fourteenth day of the onset of palsy. 
The  results  were  analysed  in  regard  to  the  usefulness  of  electrophysiological 
studies  in  prognostication  and  which  combination  of  drugs  is  most  useful  in 
management of Bells palsy.
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REVIEW OF LITERATURE
Historical review 
              As early as 1821, Sir Charles Bell discovered that the facial nerve is  
responsible  for  facial  muscle  movement  (Bell,  1821).  Soon  thereafter,  the 
recognition of the anatomic basis of facial nerve injury gave way to reconstructive 
strategies.  The  first  facial  nerve  repair  was  performed  in  1879  by  Drobnick 
Bunnell. He attempted an intratemporal repair of the facial nerve in its fallopian 
canal course.
           In  1971,  Thompson  became  one  of  the  pioneers  in  free  muscle 
transplantation  without  vascular  microanastomosis.  He discovered that  the  best 
results  were  achieved  when  the  graft  had  been  denervated  2-3  weeks  before 
transplantation. In 1973, May and Miehlke successfully conducted the fascicular 
spatial  orientation  (motor,  secretory,  afferent)  of  the  facial  nerve.  Scaramella 
pioneered cross-facial nerve grafts as a technique of coapting contralateral intact 
facial nerves to injured facial nerve. 
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Harii  et  al  broached  microneurovascular  free  muscle  transplantation  for  the 
reconstruction of the paralyzed face in 1976. This group performed a free gracilis 
muscle transfer for the reconstruction of a smile with excellent results. 
Facial Nerve- Anatomic Considerations
                 The seventh cranial nerve is mainly a motor nerve supplying all the 
muscles concerned with facial expression on one side. The sensory component is 
small (the nervus intermedius of Wrisberg). It conveys taste sensation from the 
anterior two – thirds of the tongue and, variably, cutaneous sensation from the 
anterior  wall  of  the  external  auditory  canal.  The  taste  fibers  first  traverse  the 
lingual nerve (a branch of the trigeminal) and then join the chorda tympani, which 
convey taste sensation via the facial nerve to the nucleus of the tractus solitarius. 
Secretomotor fibers innervate the lacrimal gland through the greater superficial 
petrosal  nerve  and the  sublingual  and  submaxillary  glands  through the  chorda 
tympani.
Several other anatomic facts are worth remembering. The motor nucleus of 
the  seventh  nerve  lies  ventral  and  lateral  to  the  abducens  nucleus,  and  the 
intrapontine fibers of the facial nerve partly encircle and pass ventrolaterally to the 
abducens nucleus before emerging from the pons, just lateral to the corticospinal 
tract. At their juxtaposition in the floor of the upper fourth ventricle, the sixth and 
seventh nerves may be affected simultaneously by a vascular or infiltrative lesion. 
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The facial nerve enters the internal auditory meatus with the acoustic nerve and 
then bends sharply forward and downward around the anterior boundary of the 
inner ear. At this angle (genu) lies the sensory ganglion (named geniculate because 
of its proximity to the genu). The nerve continues in its own bony channel, the 
facial  canal,  within  which.  1st  distal  to  the  geniculate  ganglion,  it  provides  a, 
branch to the pterygopalatine ganglion, i.e., the greater superficial petrosal nerve; 
somewhat more distally, it gives off a small branch to the stapedius muscle and is 
joined by the chorda tympani. It makes its exit from the skull at the stylomastoid 
foramen, then passes through the parotid gland and subdivides into five branches 
that  supply  the  facial  muscles,  the  stylomastoid muscle,  the  platysma,  and the 
posterior belly of the digastric muscle.
A complete  interruption of  the  facial  nerve at  the stylomastoid foramen 
paralyzes all muscles of facial expression. The corner of the mouth droops, the 
creases  and skin  folds  are  effaced,  the  fore  head  is  unfurrowed,  the  palpebral 
fissure is widened, and the eye lids will not close. Upon attempted closure of the 
lids, both eyes roll upward (Bell’s phenomenon), but the one on the paralyzed side 
remains visible.  The lower lid sags also, and the punctum falls away from the 
conjunctiva, permitting tears to spill  over the cheek. Food collects between the 
teeth and cheek, and saliva may dribble from the corner of the mouth. The patient 
complains of a heaviness or numbness and sometimes an aching pain in the face, 
but sensory loss can usually not be demonstrated. Taste, however, is intact because 
the lesion is beyond the site where the chorda tympani has separated from the 
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main trunk of the facial nerve.
           If the lesion is in the facial canal above the junction with the chorda tympani but 
below the geniculate ganglion, all the preceding symptoms occur. In addition, taste is lost 
over the anterior two- thirds of the tongue on the same side.                         If the nerve to 
the stapedius muscle is involved, there is hyperacusis (painful sensitivity to loud sounds). 
With a stethoscope in the patient’s ears, a tuning fork at the bell is louder on the side of 
the paralyzed stapedius muscle. If the geniculate ganglion or the motor root proximal to it 
is involved, lacrimation and salivation may be reduced. Lesions at this point may also 
affect the adjacent eighth nerve, causing deafness, tinnitus, or dizziness
Bell’s palsy
                Bell-s palsy is an idiopathic peripheral disease of the seventh cranial 
nerve. This is the most frequent cranial mononeuropathy with an annual incidence 
of 10 to 40 cases per 100,000 population with geographical variations.  1, 4 It can 
occur at any age, but mostly in the third and fourth decade of life. The disease was 
described as a distinct entity by Sir Charles Bell in 1893, and since then it has 
commonly been referred to as Bell's palsy. It is seen as often in men as in women. 
Those at high risk include pregnant women and people with diabetes mellitus. 
About 10% of those with Bell’s palsy have a family history of the condition. 
          Each facial nerve travels through a narrow bony canal in the skull beneath 
the ear to the muscles on each side of the face. Acute inflammation and edema of 
the facial nerve are thought to lead to entrapment of the nerve in the bony canal, 
which leads to compression ischemia. An observation that supports the hypothesis 
of  an  inflammatory  etiology  is  that  the  facial  nerve  shows  enhancement  on 
magnetic resonance imaging (MRI) in patients with acute Bell palsy. 5
Etiology and role of herpes simplex virus 
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                 Events, such as viral infection 6, 7, 8, ischemia 9, and autoimmune reaction 
10, have been proposed as causes of Bell’s palsy. Viral infection is thought to be the 
most likely cause  11. However, it is rare to find a diagnostic fourfold increase in 
specific  viral  antibody titer  in  the  acute  and convalescent serum specimens  of 
patients with Bell palsy 7, 8,. Postmortem histopathologic studies of the facial nerve 
suggest  viral  neuritis 12,  but  electron  microscopic  studies  have  failed  to  detect 
specific viral particles in the facial nerve 13. 
                 Polymerase chain reaction assays have identified herpes simplex virus 
in the endoneurial fluid, posterior auricular muscle, and saliva in patients with Bell 
palsy.  14,15 Shingo Murakami,  MD et  al  analyzed the viral  genomes of herpes 
simplex virus type 1 (HSV-1), varicella-zoster virus, and Epstein-Barr virus using 
polymerase chain reaction (PCR) on facial nerve endoneurial fluid specimens and 
specimens  of  posterior  auricular  muscle  on  patients  who  have  undergone 
decompression surgery. They found HSV-1 DNA in 11 of 14 patients (79%) with 
Bell  palsy  and  varicella-zoster  virus  DNA  in  8  of  the  9  patients (89%)  with 
Ramsay-Hunt syndrome. Hence they conclude Herpes simplex virus type 1 as the 
major etiologic agent in Bell’s palsy14.
Clinical characteristics of Bell palsy include:
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• Peripheral dysfunction of the facial nerve, involving all distal branches
• Abrupt onset (over hours), with maximal facial weakness at 24 to 72 hours
• Unilateral facial weakness that is complete in most patients, but may be partial
in as many as one third of patients
• Numbness or pain around the ear on the affected side
• A reduction in taste on the affected side; altered taste on the anterior two thirds 
of tongue
• Hypersensitivity to sounds (hyperacusis) on the affected side, found in one third 
of patients
• Spontaneous improvement within 6 months in most cases 16
• Incomplete healing in 15% of patients, resulting in residual nerve dysfunction, 
including  partial  palsy  and  motor  synkinesis  (involuntary  movement 
accompanying a voluntary one).
.            Also, there should be no signs and symptoms of middle ear disease and 
posterior fossa disease. There should not be any history of trauma, local infection, 
tumor,  or  other  central  nervous  system  disease. The  diagnosis  of  idiopathic 
peripheral facial palsy (PFP) is established by excluding all other possible causes.
Symptoms and signs indicative of possible additional pathology
1. Ear ache, hearing loss
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2. Pain or paraesthesia
3. Any abnormality on otoscopy—including otitis media
4. Associated cranial neuropathies or other neurological signs
5. Hypertension
6. Lymphadenopathy, pallor or bruising
7. Vesicles in external meatus or on soft palate
8. Single branch involvement
9. Gradual progression of paralysis beyond 3 weeks
10. Recurrence
11. Mastoid swelling  
 House-Brackmann facial nerve grading system 17 can be used to quantify the 
damage.
HOUSE-BRACKMANN---FACIAL NERVE GRADING SYSTEM
          Grade                                     Definition
         Gross          Rest                   Motion
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Normal           -I  
              
Normal Normal Normal
Mild               -II Slight weakness 
on Close 
inspection  
  
Symmetry + Fore head –Good 
movement.  
Eye-closure with minimal 
effort. 
Mouth –Slight asymmetry
Moderate      -III Obvious Symmetry + Forehead-mild to moderate 
movement.
Eye-Closure with maximum 
effort 
Mouth- slight weakness with 
maximum effort. 
Mod to Severe. - 
IV              
Obvious & 
Disfiguring 
Symmetry + Forehead-No movement. 
Eye-Inability to close with 
maximum effort.
Mouth—Asymmetric 
movement with maximum 
effort. 
Severe            - V Only barely 
perceptible 
motion 
Asymmetry Forehead-No movement. 
Eye-Incomplete closure.
Mouth-Only slight 
movement. 
Total              -VI No movement No movement No movement.
DIAGNOSIS
           The history and physical examination provide the information which is a 
key to the diagnosis of Bell palsy. Most patients do not require any laboratory 
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testing  or  imaging  studies.  However,  patients  who  have  persistent  weakness 
without significant improvement, involvement of other cranial nerves, or a second 
episode of palsy require further investigations.
IMAGING
Computed tomography (CT) or MRI is indicated in the following cases:
                 • No improvement in facial paresis after 1 month
                 • Hearing loss
                 • Multiple cranial nerve deficits
MRI with gadolinium is the test of choice
                 If patient has signs of limb paresis or sensory loss to rule out 
                 Cerebellopontine angle tumor,
                 Stroke, 
                 Multiple sclerosis, or other structural lesions. 
CT scan brain is recommended if a temporal bone fracture is suspected.
ENT evaluation
If hearing loss is suspected, then audiometry testing can be performed to 
substantiate hearing loss and also help to rule out acoustic neuroma.
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Laboratory evaluation.
Laboratory  testing  is  necessary  if  the  patient  has  signs  of  systemic 
involvement  such  as  fever,  weight  loss,  rash,  or  progressive  facial  weakness 
without significant improvement for more than 4 weeks. Number of tests may be 
helpful:
Complete blood count helps to rule out lymphoreticular malignancy, the 
first manifestation of which may be peripheral facial palsy. 18
Blood glucose should be measured if diabetes mellitus is suspected.
Serum  antibodies against  herpes  zoster  and  Borrelia  burgdorferi  (the 
causative agent of Lyme disease) can be checked if the patient has signs such as 
vesicular lesions on the external ear or if the patient lives in an area where Lyme 
disease is endemic.
 Serum  calcium  and  angiotensin-converting  enzyme levels  should  be 
tested if sarcoidosis is suspected.
Cerebrospinal  fluid  testing is  helpful  if  infection  or  malignancy  is 
suspected;  however,  cerebrospinal  fluid  taken  from  patients  with  Bell’s  palsy 
tends to show mild and inconsistently elevated cell counts and protein levels, but 
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is otherwise not helpful in identifying the cause.
Electrodiagnostic testing is not routinely done in Bell palsy. It is not very 
reliable when Bell’s palsy is in the initial stages. However, after 2 weeks, it may 
detect denervation and demonstrate nerve regeneration.
However, in order to prevent irreversible axonal damage, a diagnosis and 
an  early  prognostication  of  the  course  of  the  illness  are  necessary.  The 
pathological process that causes muscle palsy attains a peak during the first two 
days of illness, but it can have progressive course for 7-10 days, too. Because of 
these potentially dynamic damages, each prognostic procedure based on clinical 
manifestation in the early stage of illness is limited. Nevertheless, the lack of any 
movement of mimic musculature during the first four weeks of illness suggests a 
bad prognosis  3,16.  Electrophysiological  tests  may offer  valuable  information in 
defining the  severity  of  nerve injury  and possible  subsequent  dysfunction.  For 
these  reasons,  these  tests  could  be  significant  prognostic  parameters.  Previous 
electrophysiological  investigations  point  to  a  special  prognostic  value  of  the 
amplitude of Compound muscle action potential (CMAP) in Bell's palsy, since the 
CMAP amplitude depends on the number of excitable axons. As the nerve fibres 
degenerate the CMAP amplitude decreases. The degree of degeneration of nerve 
fibers is directly proportional to the decrease in the CMAP amplitude  19,  20,  21,  22. 
Essen 23 and Fish 21 emphasized the decrease in the CMAP amplitude of more than 
90%, compared to the healthy side, as a bad prognostic sign. This decrease in the 
CMAP amplitude is cited in literature as the main criterion for the decision of a 
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surgical decompression. The diagnostic and prognostic value of the CMAP latency 
was discussed and disputed in previous studies.  Since the CMAP latency reflects 
the function of the fastest axons, it can remain within a normal range for a long 
time.  Although  the  amplitude  and  the  latency  of  CMAP  provide  valuable 
information on the distal parts of the nerve damage rate, we cannot estimate the 
conductivity  of  the  intracranial  segment  of  the  nerve  using  these 
electrophysiological parameters. Consequently, Blink Reflex plays an important 
role  in  the  evaluation  of  the  proximal  segments  of  the  seventh  cranial  nerve 
function  and  in  detection  of  the  intracranial  conduction  block  as  the  main 
electrophysiological substratum in Bell's palsy  19,  24. Therefore, it is a significant 
prognostic  parameter.  Electromyography  (EMG)  investigation  of  the  muscles 
allows  for  the  registration  of  action  potentials  of  motor  units,  as  well  as 
spontaneous and insertional  activity  of  the  muscles.  It  is  understood that  total 
absence of action potentials during voluntary contractions is a bad prognostic sign 
2, 4, 25, 26, 27, 28. 
Treatment 
             Treatment of Bell’s palsy is still controversial. Therapy is difficult to 
evaluate,  because  as  many  as  two  thirds  of  patients  with  Bell’s  palsy 
spontaneously recover and achieve near-normal function. Many patients begin to 
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improve as early as 10 days after the onset, even without treatment.
                  Older patients are less likely to recover completely. In a series of 250 
patients at an ear, nose, and throat clinic in Greece, the percentage of patients who 
recovered completely varied from 74% to 83% in patients aged between 4 and 50, 
whereas the percentage was less than 54% at age 80 and above. 29
Protection of the eyes
            To prevent exposure keratitis, artificial tears should be used frequently 
during the day in the affected eye to keep it moist. Sunglasses should be worn. 
Areas with air,  contaminated by excessive particulate matter or  noxious fumes 
(construction  areas,  textile  factories)  should be  avoided.  To protect  the  cornea 
during sleep, an ophthalmic ointment should be used along with an eye patch. Any 
corneal  abrasion  or  infection  should  be  treated  immediately  to  avoid  possible 
visual  complications.  Ophthalmologic  consultation  is  recommended  if  any 
deterioration in visual function is noted.
Drug therapy
           Drug therapy mainly consists of corticosteroids with or without an antiviral 
drug (acyclovir). These drugs hasten the recovery and lessen the ultimate degree 
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of  dysfunction.  30,  31,  32     If  the  patient  presents  10  days  after  the  onset  of 
symptoms, no drug treatment is necessary. 
Corticosteroids.
           A study of 239 patients showed improved rates of synkinesis (involuntary 
movement accompanying a voluntary one) after treatment with prednisolone 60 
mg/day for 10 days and then tapered over 1 week, compared with placebo33.  The 
most commonly reported regimen was 1 mg/kg of oral prednisolone, up to 70 mg 
per day, split into twice-daily dosing. The starting dose was continued for 6 days, 
and then tapered off over a subsequent 4 days.  Corticosteroid therapy reduces 
autonomic synkinesis and possibly improves the rate of recovery in adults. No 
study showed significantly  worse facial  functional  outcomes in patients  treated 
with  steroids.  Four  out  of  five  studies  done  demonstrated  a  trend  for  better 
outcomes in the steroid treated patients.
Corticosteroids plus Acyclovir.
          Treatment with antivirals seems logical in Bell’s palsy because of the 
probable  involvement  of  herpes  viruses.  Acyclovir,  a  nucleotide  analogue, 
interferes  with  herpes  virus  DNA  polymerase  and  inhibits  DNA  replication. 
Because of  acyclovir’s  relatively poor bioavailability  (15% to 30%),  18 newer 
drugs in its class are undergoing trials. Better bioavailability, dosing regimens, and 
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clinical  effectiveness  in  treating  shingles  have  been  shown  with  valaciclovir 
(prodrug of acyclovir), famciclovir (prodrug of penciclovir), and sorivudine.
           Adding acyclovir to prednisolone therapy may improve recovery rates 
compared  with  prednisolone  alone.  A  practice  parameter  from  the  American 
Academy of Neurology states that corticosteroids are safe and probably effective, 
and that acyclovir is safe and possibly effective.34   Early treatment (i.e., within 3 
days after the onset of Bell palsy) is necessary for acyclovir prednisolone therapy 
to be effective35 .  However, drug therapy may also be effective if started with in 
10 days  of  symptom onset. Adour  et  al32 found that  92% of  patients  regained 
normal facial motion when given a 10-day course of prednisolone (60 mg a day 
orally for 5 days, tapered by 10 mg a day for 5 days) and acyclovir (200 mg by 
mouth five times daily).
           The outcome of patients treated with prednisolone plus acyclovir was 
superior  to  the  outcome  of  those  treated  with  prednisolone  plus  placebo,  and 
prednisolone plus acyclovir was “statistically more effective in producing return of 
volitional muscle motion.32 Adour et al suggest that if  a  patient  presents within 1 
week of the onset of facial weakness and if he or she  is not a  diabetic or pregnant 
and has no signs of infection, should receive prednisolone (60  mg/day for 5 days 
and then a slow taper over 5 days) plus acyclovir (200 mg five times per day for 
10  days).  Oral  valaciclovir,  which  is  converted  in  the  body  to  acyclovir,  has 
greater  bioavailability  than  oral  acyclovir  and  yields  similar  acyclovir  plasma 
concentrations with only twice-daily dosing 36
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Corticosteroids Vs Acyclovir.
         Acyclovir has been compared with prednisolone.   A study comparing 
prednisolone vs acyclovir found that patients treated with prednisolone had better 
and complete recovery rates, 93.6% vs 77.7%.37  Using acyclovir (or any antiviral) 
without steroids is not advised  unless steroids are contraindicated
Further study needed
A larger multicenter double-blind placebo-controlled trial in the future may shed 
more light on the efficacy of steroids and antiviral therapy.
Surgical treatment
       There is no enough evidence to recommend surgical decompression of the 
facial  nerve  to  hasten  the  recovery  in  patients  with  Bell  palsy.  Surgical 
decompression for indications other than trauma is controversial  31,  38. However, 
some surgeons still offer middle fossa decompression if electromyography shows 
a  90% reduction  in  compound  muscle  action  potential  in  patients  with  facial 
weakness lasting less than 3 weeks 39. For a patient with permanent facial paralysis 
despite  medical  and  surgical  treatment,  many surgical  options  are  available  to 
improve facial function and appearance. These include static sling procedures with 
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facia  lata  or  alloplastic  strips;  dynamic  procedures  with  transposition  of  the 
temporalis or masseter muscle; hypoglossal-facial nerve anastomosis; crossfacial 
nerve grafting; free muscle grafting; and microvascular free nerve muscle grafting.
            Persistent facial weakness has considerable functional and cosmetic 
implications.  Disfigurement can lead to significant psychosocial morbidity.  The 
small  numbers  of  patients  falling  into  this  group  require  expert  assessment. 
Feedback training and exercise programmes have been shown to provide some 
benefit in patients with long standing facial nerve paralysis. Surgical techniques 
aimed  at  improving  function  and  cosmetics;  include  nerve  repair,  graft,  or 
transposition. Nerve transposition involves attaching the distal end of the affected 
facial nerve to another afferent cranial nerve trunk, for example, the contralateral 
facial nerve, or a hypoglossal “jump graft”. This technique must be undertaken 
within two years of paralysis. Muscle transposition, or microneurovascular free 
muscle transfer, can also be considered.
              In summary, patients presenting with acute lower motor neuron facial 
paralysis require a thorough physical examination. Full neurological examination, 
otoscopy, and blood pressure measurement are mandatory. In the absence of any 
abnormal symptoms or signs, further investigation is unnecessary. To date there is 
no clear evidence that any form of treatment improves outcome of idiopathic facial 
palsy.  Protection  of  the  cornea,  with  artificial  tears  and  overnight  patching,  is 
normally all that is required. Follow up is advisable
27
Electrotherapy
The use of electrotherapy in the treatment of Bell palsy remains controversial.
Facial exercise
Facial  exercises  can  be  beneficial  in  patients  with  Bell  palsy.  They should  be 
performed while  standing  in  front  of  a  mirror  and  include  trying  to  raise  the 
eyebrows, opening and closing the eyes, blowing, and whistling. These exercises 
can be performed a few times daily.40,41 The efficacy of exercise has not been 
formally evaluated.
Botulinum toxin injections
             Motor synkinesis can occur during recovery from Bell’s palsy, due to 
aberrant regeneration of the facial nerve. It can be grossly deforming. Injection of 
botulinum toxin into the involved muscles is an effective treatment. Hemifacial 
spasm occasionally appears after Bell’s palsy, and blepharospasm can be seen in 
rare cases.42.  Both can be treated with injections of botulinum toxin. The time from 
the resolution of Bell’s palsy to the subsequent development of blepharospasm 
ranges from a few weeks to 24 years.42.  Hyperlacrimation secondary to aberrant 
regeneration of the seventh nerve has also been reported after Bell’s palsy. 
Botulinum toxin injection has been used in these patients.
28
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AIMS OF THE STUDY
1) To assess the Prognostic Value of Electrophysiological Tests in management of 
Bell’s palsy
2) To assess the efficacy of Steroids and Acyclovir in management of Bell’s palsy.
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MATERIALS AND METHODS
                This prospective study was done on 101 patients with clinical signs of 
Bell's palsy, of both sexes, in various age groups who attended the Neurology Out 
patient  department,  Institute  of  Neurology.  Madras  Medical  College  and 
Government General Hospital, Chennai, from 01-06-2005 to 01-03-2006. All the 
patients underwent Neurological and ENT evaluation.
Inclusion criteria
              All the patients with Bell's palsy, without clinical evidence of other 
cranial nerve damage or central nervous system diseases. 
Exclusion criteria
          Patients with,  
                Middle ear disease or posterior cranial fossa disease.
                Chronic illness like Diabetes mellitus, Hypertension and 
                Malignancy 
were excluded from the experimental group since they may affect the prognosis of 
the disease. 
            Treatment of the patient was decided by the treating neurologist in the out 
patient  department  and  depending  on  the  treatment  they  receive  the  patients 
included in the study are categorized into 4 groups.
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Group 1-Patients who received only physiotherapy (Control)
Group 2- Patients who received steroids and physiotherapy.
Group 3- Patients who received steroids, acyclovir and physiotherapy.
Group 4- Patients who received Acyclovir and physiotherapy. .
       In the treatment group dosage of steroids used is 1 mg /kg (45 to 60) mg for 5 
days then tapered over next 5 days. Acyclovir is used in dose of 1 gm / day for 10 
days32.  The  severity  of  the  facial  nerve  involvement  is  assessed  with House-
Brackmann grading (HB) system 17.
           HOUSE-BRACKMANN---FACIAL NERVE GRADING SYSTEM
          Grade                                     Definition
         Gross          Rest                   Motion
Normal           -I 
              
Normal Normal Normal
Mild               -II Slight weakness 
on Close 
inspection  
  
Symmetry + Fore head –Good movement.  
Eye-closure with minimal effort. 
Mouth –Slight asymmetry
Moderate      -III Obvious Symmetry + Forehead-mild to moderate 
movement.
Eye-Closure with maximum effort 
Mouth- slight weak with 
maximum effort. 
Mod to Severe. - 
IV              
Obvious & 
Disfiguring 
Symmetry + Forehead-No movement. 
Eye-Inability to close with 
maximum effort.
Mouth—Asymmetric movement 
with maximum effort. 
Severe            - V Only barely 
perceptible 
motion 
Asymmetry Forehead-No movement. 
Eye-Incomplete closure.
Mouth-Slight movement. 
Total              -VI No movement No movement No movement.
   Grading was done on first visit and on 14th day, 1st, 2nd , 3rd , 6th , 9th  and 12th 
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months to assess the improvement, response to treatment and complications due to 
the disease and treatment in the various treatment groups.
Nerve conduction study was performed on the 14th day or on the first visit 
of the patient to the hospital. 
            For the CMAP examination, supramaximal stimulation was applied for 0.2 
ms  duration  over  the  trunk  of  the  facial  nerve,  using  the  bipolar  stimulating 
electrode with the anode between the ramus of mandible and the mastoid and the 
cathode in front of the tragus of the ear. The CMAP was recorded with a plate 
electrode  in  the  target  muscles,  orbicularis  oculi,  and  orbicularis  oris.  The 
amplitude and the latency of the CMAP were analysed.
             The mean amplitudes on the affected side were computed as percentage 
ratio of the normal amplitudes on the healthy side (taken as 100%). The patients 
were grouped according to the ratio into three groups 2:
      1)  A (30 -100%),
      2)  B (10-30 %), 
      3)  C (less than 10% or not stimulatable).
             The latency of the CMAP was also recorded in the same muscles on both 
34
the healthy and affected side. The corresponding mean value was computed, and 
the patients were grouped according to the latency recorded into three groups2.
    1)  A (not greater than 4 ms), 
    2)  B (More than 4 ms), and group
    3)  C with no CMAP recorded.
            In order to estimate prognostic values, the electrophysiological parameters, 
of  amplitude  and latency  of  the  CMAPs  were  correlated  with  the  duration  of 
clinical recovery.
            The study groups of patients were clinically tested in a periodic manner 
within twelve months at various intervals. Based on the clinical recovery, patients 
were divided into four groups:
 A − with recovery during the first two months,
 B − recovery within 2-6 months,
 C − recovery within 6-12 months, and
 D − incomplete recovery after 12 months.
             A functional recovery of the seventh cranial nerve was classified based on 
House-Brackmann (HB) system 17.According to House-Brackmann grading (HB) 
system the patients were classified into six groups. For analysis, grading done after 
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second week was taken, because a certain number of patients had a neurological 
deficit, which had been changing during the first two weeks of the illness.
  Chi  Square  test  is  employed to  test  the  difference  between an  actual 
sample and another hypothetical or previously established distribution such as that 
which may be expected due to chance or probability. A probability of .05 or less is 
considered to be a significant. 
  Relative  rate  is  used  frequently  in  the  statistical  analysis  of  binary 
outcomes where the outcome of interest has relatively low probability. It is thus 
often suited to clinical trial data, where it is used to compare the outcomes, in 
people not receiving the new medical treatment (or receiving a placebo) versus 
people who are receiving an established (standard of care) treatment. In the present 
study relative rate and confidence intervals of relative rate were calculated using 
the programme written by DJR Hutchon.
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OBSERVATIONS
     One hundred and one patients with signs of the Bell’s palsy were included in 
this study.
Table 1-Age distribution
Age
    
     Control      Steroid Steroid +
 Acyclovir
   Acyclovir Total
Nos    % Nos   % Nos   % Nos   % No
s
  %
10-20 3 13 12 30 5 17.2 1 11.1 21 20.79
21-30 5 21.7 11 27.5 7 24.1 1 11.1 24 23.76
31-40 8 34.7 9 22.5 11 37.9 2 22.2 30 29.70
41-50 2 8.6 5 12.5 3 10.3 3 33.3 13 12.8
51-60 4 17.3 2 5.0 2 6.8 2 22.2 10 9.9
61-70 1 4.3 1 2.5 1 3.4 0 0 3 2.9
Total 23 40 29 9 101
38
           Most of the cases belong to the age group of 31-40. Only 2.9% of patients 
belonged to the age group of 61-70.
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Table 2-Sex distribution
Sex Control Steroids  Steroid +Acyclovir Acyclovir Total
Male 13 19 16 6 54
Female 10 21 13 3 47
Total 23 40 29 9 101
         In the present study sex ratio was almost even. 47 were females (46.6%) and 
54 were males (53.4%). 
Table 3-Grading
Grade Control Steroids Steroid + Acyclovir Acyclovir Total
I - - - - -
II - - - - -
III 5 7 6 2 20
IV 11 18 13 2 44
V 7 12 08 5 32
VI 0 3 2 - 05
Total 23 40 29 9 101
       Majority of patients come under grade IV (43.6%) and next comes grade V 
(31.7%), III (19.8%), and the least in grade VI (4.9%).
Table 4-Analysis of clinical grade and improvement in the study group
Grade  Number of patients
Good 
improvement        %
III 20 20 100
IV 44 38 86.3
40
V 32 22 68.8
VI 5 0 0
Total 101 80 79.2
        Among the  various  grades,  all  the  patients  in  grade showed complete 
improvement. 86% of percentage of patients improved in grade IV, and 68.8% of 
patients  improved  in  grade  V.  None  of  the  patients  from  grade  VI  showed 
improvement. 
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Table 5--Improvement in various age groups-Controls
Age
    
   Grade  III    Grade  IV    Grade  V Grade  VI     Total
Nos Imp Nos   Imp Nos Imp Nos Imp Nos Imp
10-20 - - 1 1  2 0 - - 3 1
21-30 1 1 3 2 1 1 - - 5 4
31-40 2 2 5   4 1 1 - - 8 7
41-50 - - -   - 2 1 - - 2 1
51-60 2 2 1   1 1 0 - - 4 3
42
61-70 - - 1   0 - - - - 1 0
Total 5 5 11 8 7 2 - - 23 15
       In the various age groups, one out of three  in 10-20 years, four out of five in 
21-30 yrs, seven out of eight in 31-40 yrs,  one out of two in 41-50 yrs, three out 
of four in 51-60 yrs and none in 61-70 yrs age groups improved.
Table 6-Improvement in various age groups-Steroids
Age
    
Grade  III Grade  IV      Grade  V Grade  VI Total
Nos Imp Nos Imp Nos Imp Nos Imp Nos Imp
10-20 1 1 2 1 7 7 2 0 12 9
21-30 2 2 9 8 1 1 - - 12 11
31-40 3 3 3 3 2 2 - - 8 8
41-50 1 1 3 2 1 1 - - 5 4
51-60 - - 1 1 1 0 - - 2 1
43
60-70 - - - -. - - 1 0 1 0
Total 7 7 18 15 12 11 3 0 40 33
             
 In the various age groups, nine out of twelve  in 10-20 years, eleven out of 
twelve in  21-30 yrs, eight out of eight in 31-40 yrs,  four out of five in 41-50 yrs, 
one out of two in 51-60 yrs and none in 61-70 yrs age groups improved.
Table 7-Improvement in various age groups-Steroids + Acyclovir
Age
    
Grade  III Grade  IV Grade  V Grade  VI Total
Nos Imp Nos Imp Nos Imp Nos Imp Nos Imp
10-20 3 3 2 2 - - - - 5 5
21-30 - - 4 4 3 3 - - 7 7
31-40 2 2 5 5 3 3 - - 10 10
41-50 1 1 2 2 1 1 - - 4 4
51-60 - - - - - - 1 0 1 0
44
61-70 - - - - 1 0 1 0 2 0
Total 6 6 13 13 8 7 2 0 29 26
      
 In the various age groups, all the patients in 10-20 years, 21-30 yrs, 31-40 
yrs, 41-50 yrs, improved and none of the patients in 51-60 yrs and 61-70 yrs age 
groups showed improvement
Table 8-Improvement in various age groups- Acyclovir
Age
    
   Grade  III Grade  IV Grade  V Grade  VI Total
Nos Imp Nos Imp Nos Imp Nos Imp Nos Imp
10-20 - - - - 1 1 - - 1 1
21-30 - - - - 1 1 - - 1 1
31-40 - - 1 1 1 0 - - 2 1
41-50 1 1 - -. 2 0 - - 3 1
51-60 1 1 1 1 - - - - 2 2
45
60-70 - - - - - - - - - -
Total 2 2 2 2 5 2 - - 9 6
       In the various age groups, all the patients in 10-20 years, 21-30 yrs, 51-60 yrs 
and one out of two in 31-40 yrs, one out of three in 41-50 yrs improved.
Electrophysiology
Table 9- Analysis of CMAP recorded in 1st week in 35 patients and recovery
Amp ratio
              
               Recovery in months
<2 2-6 >6
In complete 
recovery in 
12 months Total
A 15 8 0 3 26
B 0 3 0 5 8
C 0 1 0 0 1
Total 15 12 0 8 35
        Out of 26 patients in group A, 23 patients had complete recovery. Out of 8 
patients  in  group B,  3  patients  recovered,  and the one patient  in group C had 
recovered within 6 months
Table 10 - Analysis of CMAP recorded after 2 weeks in same 35 patients and recovery
Amp ratio
              
               Recovery in months
<2 2-6 >6
In complete 
recovery in 
12 months Total
46
A 13 1 0 0 14
B 1 9 0 1 11
C 0 1 0 9 10
Total 14 11 0 10 35
       
           All the patients in group A had complete recovery. 10 patients showed compete 
improvement in group B and of 10 cases in group C only one recovered.
        
   
15
0 0
8
3
1
0 0 0
3
5
00
2
4
6
8
10
12
14
16
N
o 
of
 p
at
ie
nt
s
< 2 mon 2-6 mon > 6 mon Incomplete
recovery
Recovery in months
 Analysis of CMAP recorded in 1st week in 35 patients and 
recovery
A
B
C
47
13
1
0
1
9
1
0 0 0 0
1
9
0
2
4
6
8
10
12
14
N
o.
 o
f p
at
ie
nt
s
< 2 mon 2-6 mon > 6 mon Incomplete
recovery
Recovery in months
 Analysis of CMAP recorded in 2nd  week in 35 patients 
and recovery
A
B
C
      CMAP recording showing decreased amplitude in the affected side
                                 
                            
CMAP of a patient who had sub clinical involvement on the other side
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Table 11-Analysis of recovery in relation to CMAP amp ratio (After 2nd week) in 
Control group.
Amp ratio
              
               Recovery in months
     <2    2-6 >6
In complete 
recovery in 
12 months
Total
A 4 2 0 0 6
B 1 7 1 1 10
C 0 0 0 7 7
Total 5 9 1 8 23
               Here all the patients in group A recovered. In group B out of 10 patients 9  
recovered and in group C none recovered.
Table 12-Analysis of recovery in relation to CMAP amp ratio (After 2nd week) in Steroid 
group
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Amp ratio
              
               Recovery in months
<2 2-6 >6
In complete 
recovery in 
12 months
Total
A 22 1 0 0 23
B 4 4 0 1 9
C 0 1 1 6 8
Total 26 6 1 7 40
          
 
             Here all the patients in group A recovered within 2 months. In group B out of 9  
patients 8 recovered and in group C out of 8 patients 2 recovered.
Table 13-Analysis of recovery in relation to CMAP amp ratio (After 2nd week) in Steroid 
+ Acyclovir group
Amp ratio
              
               Recovery in months
     <2    2-6      >6
In complete 
recovery in 
12 months
Total
A     16      1        0        0       17
B        3       3
      
       0        1         7
C        0       3
   
       0        2         5
Total      19       7        0        3       29
               All the patients in group A recovered within 2 months. In group B out of 
7 patients 6 recovered and in group C out of 5 patients 3 recovered
Table 14-Analysis of recovery in relation to CMAP amp ratio (After 2nd week) in
Acyclovir group.
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Amp ratio
              
               Recovery in months
     <2     2-6     >6
In complete 
recovery in 
12 months
Total
A       2      1      0        0      3
B       0      3      0        0      3
C       0      0      0        3      3
Total       2      4      0        3      9
               All the patients in group A and B recovered within 6 months. In group C 
none of the cases recovered.
CMAP Latency 
Table 15- Analysis of CMAP latency recorded in during 1 week and rate of recovery
Latency
              
               Recovery in months
    <2     2-6       >6
In complete 
recovery in 
12 months     Total
A      17       8
 
      0       10      35
B        0       0       0         0        0
C        0       0       0         0        0
Total        0       0       0         0      35
    During the first week the CMAP latency was within normal limits  and of the 35  
patients 10 had an incomplete recovery
 Table 16- Analysis of CMAP latency recorded in after 2 weeks and rate of recovery
Latency
              
               Recovery in months
<2 2-6 >6
In complete 
recovery in 
12 months Total
51
A      49       24      0        9      82
B        3         2       2      10      17
C        -         -       -        2        2
Total      52       26       2      21     101
            
             82 patients (81.2%) had normal latency, among these, 73 cases recovered 
within 6 months. Out of 17 who had prolonged latency, 7 patients recovered fully 
and 2 patients in group C didn’t show any improvement. 
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Rate of improvement in various treatment groups
Table 17-Control
Grade Cases Good improvement %
I - - -
II - - -
III 5 5 100
IV 11 8 72.7
V 7 2 28.5
VI 0 0 0
Total 23 15 65.21
          All the patients in grade III improved, in grade IV 72.7% improved, and in 
grade V improvement is 28.5%.
Table 18-Steroids
Grade Cases Good improvement %
I - - -
II - - -
III 7 7 100
IV 18 15 83.33
V 12 11 91.66
VI 3 0 0
Total 40 33 82.5
          All the patients in grade III improved, in grade IV 83.3% improved, in 
grade V improvement is 91.6% and none improved in grade VI.
Table 19-Steroids and Acyclovir
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Grade Cases Good improvement %
I - - -
II - - -
III 6 6 100
IV 13 13 100
V 8 7 87.5
VI 2 0 0
Total 29 26 89.65
             All the patients in grade III, IV improved, in grade V 87.5% improved,  
and none improved in grade VI.
Table 20-Acyclovir
Grade Cases Good improvement %
I - - -
II - - -
III 2 2 100
IV 2 2 100
V 5 2 40
VI - - -
Total 9 6 66.66
All the patients in grade III and IV improved; in grade V improvement is 40%.
Table 21-Rate of improvement in various treatment groups 
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Groups Total cases Patients improved %
1—Control 23 15 65.2
2—Steroids 40 33 82.5
3—Acyclovir + Steroids 29 26 89.6
4—Acyclovir 9 6 66.6
          The improvement in group 1 was 65.2%; group 2 recorded an improvement 
of  82.5%.  Group  3  showed  maximum improvement  (89.6%)  and  group  4  the 
improvement is only 66.6%
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Table 22-Control
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Grade
No of 
cases
                 Duration for improvement
2-4 
wks
4-6 
wks
6-8 
wks
3 
months
6 
months
12
months
No of cases 
improved
I - - - - - - - -
II - - - - - - - -
III 5 - - 4 1 - - 5
IV 11 - - 1 6 1 - 8
V 7 - - - - 1 1 2
VI - - - - - - - -
Total 23 - - 5 7 2 1 15
        In the control group the improvement started by 6-8 weeks
Table 23-Steroids
Grade
No of 
cases
                  Duration for improvement
2-4 
wks
4-6 
wks
6-8 
wks
3 
months
6 
months
12
months
No of 
cases 
improved
I - - - - - - - -
II - - - - - - - -
III 7 1 4 2 - - - 7
IV 18 - 7 7 1 - - 15
V 12 - - 5 3 2 1 11
VI 3 - - - - - - 0
Total 40 1 11 14 4 2 1 33
        
            Improvement started as early as 2-4 weeks and majority of the patients  
had complete improvement within 8 weeks.
Table 24-Steroids + Acyclovir
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Grade
No of 
cases
                  Duration for improvement
2-4 
wks
4-6 
wks
6-8 
wks
3 
months
6 
months
12
months
No of 
cases 
improved
I - - - - - - - -
II - - - - - - - -
III 6 2 4 - - - - 6
IV 13 - - 8 5 - - 13
V 8 - 1 4 2 - - 7
VI 2 - - - - - - -
Total 29 2 5 12 7 - - 26
               Improvement started as early as 2-4 weeks and majority of the patients  
had complete improvement within 8 weeks. All patients recovered within 6 
months.
Table 25-Acyclovir
Grade
No of 
cases
                  Duration for improvement
2-4 
wks
4-6 
wks
6-8 
wks
3 
months
6 
months
12
months
Total 
cases 
improved
I - - - - - - - -
II - - - - - - - -
III 2 - - 2 - - - 2
IV 2 - - - 2 - - 2
V 5 - - - 2 - - 2
VI - - - - - - - -
Total 9 - - 2 4 - - 6
        In the above group the improvement started by 6-8 weeks.
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Time taken for improvement in various groups
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Table 26--Analysis of onset of treatment with improvement in group C (by 
CMAP ratio)
        Grade IV
           N =4
          Grade V 
             N =4
          Grade VI
              N =5
Recovered      Not recovered Recovered Not recovered Recovered Not recovered
Early 
treatment
      2       0       3       0       0       2
Late 
treatment
      0       2       0       1       0       3
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Table 27-Complications
Complications Control group Treatment group
Hemifacial spasm 2  ( one improved other not improved) 1
Jaw winking 1  (not improved) 0
Table 28-Complications due to steroids
Complications Group No. of patients Age & Sex
Dyspepsia Steroids 2 65 f & 60 m
Melena Steroids 1 34 m (Alcoholic)
Vomiting Steroids + Acyclovir 1 47 f
Table 29-Associated findings
Findings No. of  patients
Antenatal patients 3
Bilateral bell’s palsy               1
Recurrent bell’s palsy            3
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DISCUSSION
              The study included 101 patients of different age and sex. Sex ratio was 
almost even (47 women – 46.6%, 54 men – 53.4%). The youngest patient was 11, 
and the oldest was 65 years old. 
                The analysis of the age groups showed that the incidence of bells palsy 
is more common among the younger age group. As the age advances the incidence 
decreases, with 29.7%   in 31-40-age group and 3% in 60-70 age group.
               Grading was done in second week of disease and analysis of it shows 
majority of patients come under grade IV (43.6%) , next comes grade V (31.7%), 
III (19.8%), and the least in grade VI (4.9%)
             One patient had bilateral disease which improved completely with steroids 
with out any residual deficit. Three patients had recurrence of bell’s palsy on same 
side intervened by an asymptomatic period of six, two and ten years respectively 
who also completely recovered.
          During the study period three antenatal patients were encountered, two with 
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grade IV weakness and one with grade V weakness. The patients who had grade 
IV weakness fully improved. The other patient didn’t have complete recovery and 
developed jaw winking.
      An outcome of grade I or II using the House  and Brackmann facial function 
scoring system, is considered as good recovery
Age and improvement 
           Mathews WB et al in his study observed that older age can badly influence 
the course of the illness  16 .Heath et al  43 presented the results of their research 
showing that the average age of patients who had a rapid and complete recovery 
was 35.8 ± 15.9 years, while patients with an incomplete recovery were 55.4 ± 
18.8  years  old.  The  results  of  this  study  had  not  shown  the  existence  of  a 
correlation between the age and the duration, degree of clinical recovery. However 
it  is  necessary  to  point  out  that  older  individuals  had  poor  recovery  when 
compared  to  younger  individuals.  But  in  these  individuals  the  other  factors 
responsible for poor recovery like, severe degree of weakness, very low CMAP 
amplitude were  present.
          Hence the delayed recovery cannot be attributed to age alone; as the other 
above mentioned factors may also have contributed to the delayed recovery. These 
results  differ  from data  found in  literature,  which  show that  an  unsatisfactory 
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course of the illness can be expected in patients over 45 years of age 16, 43. 
Analysis of clinical grade and improvement in the study group
            Gordana Djordjević, Stojanka Djurić et al have shown in their  clinical 
research that, in certain number of patients had a changing neurological deficit, 
during the first two weeks of the illness. They suggesting that the prognosis based 
on the degree of motor deficit was significantly limited in the early stage of the 
illness. 44
               The poor correlation between the degree of the paresis in the early stage 
of the illness, and duration, degree of recovery was observed in the present series 
also. These observations shows that the degree of motor deficit noted in the first 
week of the illness was not a clinically reliable parameter in prognosticating  the 
duration of clinical recovery in Bell’s palsy. However the clinical grading at 2 
weeks when the deficit has stabilized showed correlation with recovery.
                  It was noted by May M et al and Hauser WA et al 26, 45 that majority of 
patients with signs of an incomplete facial paralysis of the third and fourth degree, 
on the fourteenth day of the illness, had a rapid and complete recovery. 
             The present study shows that patients with signs of an incomplete facial 
paralysis of third and fourth degree, on the fourteenth day of the illness, had a 
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rapid and complete recovery. On the other hand, none of the patients in grade VI 
recovered  within  12  months  irrespective  of  the  treatment  they  had  received 
showing that severity of illness was another prognostic factor. These patients on 
clinical observation showed the sign of a complete paralysis of mimic musculature 
(VI  degree  according  to  H-B)  of  one  half  of  the  face  at  two weeks  of  onset. 
Improvement in grade V was better when compared to grade VI. In this group rate 
of  recovery was affected by the  treatment  they received and how early  it  was 
started.
        These results showed that an incomplete facial paralysis had a complete 
clinical recovery, while a complete paralysis  indicated bad prognosis,  which is 
consistent with the literature data.  26,45 An absolute bad prognostic sign was the 
lack of any movement of the mimic musculature during the first four weeks.
CMAP amplitude 
1st week
            The results this study showed that progressive decrease of the amplitude 
was  registered  from  the  seventh  to  the  fourteenth  day  of  the  illness. 
In this study out of 101 cases registered, electrophysiological studies were done on 
thirty five patients in the first week and repeated on the second week. In the other 
cases electrophysiological studies were done on the fourteenth day of the illness or 
on the day of first visit to the hospital.
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          Analysing the CMAP amplitude recorded in the first week and duration of 
recovery, out of 26 patients in group A, 23 patients had complete recovery and 3 
patients did not recover at all. Out of 8 patients in group B, 3 patients recovered 
and 5 didn’t recover and the one patient in  group C had complete recovery within 
6 months which didn’t correlate with observations already made.
         Analysing the CMAP recorded in the second week of the illness in the above 
35 patients all the patients in group A had complete recovery. Out of 11 patients in 
group B, 10 patients showed complete improvement and out of 10 cases in group 
C only one recovered. This observation showed CMAP recorded in second week 
was very helpful  in assessing the prognosis  of  the disease  44.  This  observation 
correlates with Esslen's reports 23 who showed that the CMAP amplitude decrease 
is recorded from the third to the tenth day, while Hitoshi et al46 in their results 
showed that  this  decrease  occured in  the  first  seven days  and remained stable 
thereafter. 
                 Analysing the CMAP recorded in the second week in this study out of 
101 patients 49 patients comes under group A, where all the cases recovered 
within six months and 44 patients (88%) had complete recovery within two 
months, remaining 5 cases recovered in 2-6 months among these 5 patients who 
took more time for recovery, 2 cases belong to control group and each one from 
other treatment group.
                         Among the 29 cases under group B, 3 patients didn’t have  
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complete recovery. Among the 26 patients who had complete recovery, 8 patients 
recovered within 2 months, 17 patients recovered within 2-6 months and only one 
patient had delayed recovery taking more than 6 months. The observation implies 
in Group B 86% of cases recovered within 6 months.  
           Out of 23 patients categorized in Group C, 5 cases recovered completely, of 
which 4 cases within 6 months and one case took more than 6 months to recover. 
Above observation makes it clear that if the CMAP amplitude is less than 10 % of 
the normal side the prognosis is poor
              The results observed on the fourteenth day of the illness showed a strong 
positive correlation between the rate of recovery and CMAP amplitude. The more 
the  amplitude  is  decreased,  the  slower was the  recovery.  Most  of  the  patients 
whose amplitude was more than 30 % of the normal side recovered completely 
during the first two months, suggesting mild damage of the nerve (neuropraxia). 
The patients whose amplitude values were between 10-30%   recovered within 6 
months  which  corresponded  to  the  second  type  of  the  nerve  damage 
(axonotemesis). The distinct amplitude decrease to (0-10%) pointed to a severe 
nerve  damage  (neurotmesis)  and  an  incomplete  clinical  recovery.  The  above 
observation correlated well with the observations made by others. 44  
            In this study there was decrease of CMAP amplitude in 7 patients in the 
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clinically normal side which did not show any motor deficit.  Among the seven 
cases, 5 cases showed this abnormality in the first week and the other two cases on 
9th and 11th  day respectively depicting sub clinical involvement on the other side 
also. Since electrophysiological studies were done only in 35 patients in the first 
week this may be an under estimation. If electrophysiological studies were done in 
the first week in all cases the identification of the sub clinical cases may be high. 
Similar observation was made by Natarajan V et al 47 who had documented 20% of 
sub clinical cases in their study.
CMAP latency. 
         The role of the CMAP latency in the early diagnosis and prognosis of Bell's 
palsy is uncertain. Although some researchers showed that abnormal latency can 
point to a bad prognosis, it is believed that this factor has a limited significance. 
Since  the  latency  reflects  the  function  of  the  fastest  fibers,  it  can  stay  within 
normal values for a long time even in cases of a distinct axonal loss. Gilliat and 
Taylor 48 reported that latency stays within normal values until the  M potential is 
lost.  However,  some  studies  have  demonstrated  that  abnormal  latency  can  be 
suggestive  of  a  bad  prognosis.  Langwort  and  Taverner  49 emphasized  that  the 
extreme  prolongation  of  the  CMAP  latency  or  absence  of  CMAP  as  a  bad 
prognostic sign. Danielides et al. have provided the results of their study made in 
1994  and  199650 which  showed  that  the  latency  extension  results  in  a  bad 
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prognosis of the illness. They also claim that the reliability of this feature was less 
important than CMAP amplitude for the prognosis.
            The results of this study shows that during the first seven days of the 
illness  latency  values  were  normal  with  or  without  a  minimal  asymmetry 
compared to the healthy part, while after the fourteenth day the prolongation of the 
CMAP  latency was above normal values in some cases . On the fourteenth day 
after the first symptom the prolongation of the latency was registered in 19 (18.8 
%) patients and the latency was within normal limits in the remaining 82 (81.2%) 
patients.
            Analysis of the CMAP latency values and the duration of the recovery 
during  the  first  week did  not  show the  existence  of  the  correlation.  After  the 
fourteenth day a strong positive correlation was registered - longer latency resulted 
in slower recovery. 
              Out of 101 patients 82 patients (81.2%) had normal latency (group A), 
among these, 73 cases recovered within 6 months. The other 9 cases who did not 
have recovery had a severe decrease in CMAP amplitude. 
               In the remaining 19 patients, 17 had prolonged latency (group B) and in 
2 patients CMAP was not obtained (group C). In this (group B) out of 17 patients 
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7 patients recovered fully and the remaining 10 patients did not recover at all. The 
patients in group B who had good recovery the amplitude belonged to group A and 
B category and the 10 patients who didn’t recover had a grossly reduced CMAP 
amplitude.
           The 2 patients in group C didn’t show any improvement. It was observed 
poor recovery is a rule if latency along with CMAP amplitude is reduced.  
           This observation showed that even though latency measurement as an 
independent factor is not much helpful in assessing the prognosis, if combined 
with the amplitude predicts the prognosis.
Treatment 
                        During the study, four groups were formulated.
Group 1-Patients who received only physiotherapy (Control)
Group 2- Patients who received steroids and physiotherapy.
Group 3- Patients who received steroids, acyclovir and physiotherapy.
Group 4- Patients who received Acyclovir and physiotherapy. .
                                                                                         
            In this study 23cases were enrolled in group 1, 40 patients in group 2, 29 
patients group 3, and 9 group 4. The age and sex, clinical grade in each group 
were comparable. 
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 Rate of recovery
            For assessing the therapeutic effect in the various groups the proportion of 
patients recovering good facial function in the treated group were compared with 
the proportion of patients recovering good facial function in the control group. 
Relative rate (RR) was calculated by means of the following formula 34
Relative rate = [A / (A+C)] / [B / (B+D)]
A = Number of patients with good recovery in treatment group
B = Number of patients with good recovery in control group 
C = Number of patients with poor recovery in treatment group
D = Number of patients with poor recovery in control group
                95% confidence interval was also calculated for the relative rate.
Relative rate--- Steroids vs Control                          ==1.265  ( 95% CI  0.90-1.76 )
Relative rate--- Steroids +Acyclovir vs Control       ==1.374  ( 95% CI  0.99-1.89 ) 
Relative rate--- Steroids +Acyclovir vs Steroids      ==1.086  ( 95% CI  0.89-1.31 )
Relative rate--- Acyclovir vs Control                       ==1.022  ( 95% CI  0.58-1.77 )
         In this study, the best functional recovery was seen in patients who were 
treated with steroids and Acyclovir. The above data was statistically significant 
when compared to control group with ‘P’ value of 0.031668.
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        Patients treated with steroids alone also had a better recovery when compared 
with control group. The data interpretation showed that, the steroid group scored 
over the control group by 1.26 times. However it was not statistically significant.
        Patients treated with steroids and Acyclovir scored over patients treated with 
steroids by 1.08 times. Patients treated with Acyclovir alone scored over control 
by 1.02 times. The above data was not statistically significant.  
            These observations correlated with other studies51,52 which says that 
steroids hasten clinical recovery in  bell’s palsy . Wolf et al have suggested that 
patients with complete facial palsy benefit most from steroids.53
                Combination of Steroids and acyclovir is definitely useful when 
compared to the control group. The combination scores over the control group by 
1.37 times which is statistically significant (P value= 0.031668). This observation 
correlated  with  the  study  made  by  Adour  and  colleagues.32 
The present study did not find any beneficial effect in treating the patients with 
Acyclovir alone.  Even though the study sample is small this observation concurs 
with  the  observation  made  by  De  Diego  JI,  et  all  in  the study  comparing 
prednisolone vs acyclovir. They found that patients treated with prednisolone had 
better complete recovery rates, 93.6% vs 77.7%. 37
              The observations made in the present study shows that the combination of 
steroid and acyclovir is  definitely  useful  in Bell’s  palsy.  Steroids are probably 
effective in management of bells palsy as they improve the rate of recovery. Out 
come in patients in whom Acyclovir alone (group 4) was used didn’t score over 
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the control group. 
  Time taken for recovery
               Analysing the time taken for improvement in the various groups,  the 
recovery  in   control  group  started  by  6-8  weeks  while  in  treatment  group 
improvement started between early by 2-4 weeks.  Moreover  on comparing the 
recovery of patients  in grade IV, with in control  group only 12.5 % improved 
within 2 months, while in treatment group more than 60 % improved within 2 
months. The above observation implied recovery starts early in treatment group 
when compared with control group. Taverner et al in his study 54, reported a trend 
for  steroid-treated  patients  to  recover  faster  than  the  control  patients,  but  the 
differences were not significant
.
Role of early treatment in bells palsy.
          
          Williamson IG et al and   May MM et al have suggested that steroids work 
best in patients with Bell’s palsy if started early.3,55 Shafshak however defers this 
observation in  his  study52.  Analysing  the  outcome of  patients  in  group C,  (by 
CMAP ratio)  those who were  treated,  five  out of  thirteen,  had good recovery. 
Among the patients who recovered, two patients had grade IV deficit and two had 
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grade V deficit, and all the cases received treatment within 3 days of the illness. In 
the eight patients who had not recovered fully, five patients had complete palsy 
(grade VI) and treatment was started late in three cases. In the other three patients 
treatment  was  started  late  and  they  belonged  to  grade  IV  and  V.  The  above 
observation implies that early treatment in cases with incomplete paralysis hastens 
the recovery and in patients with complete paralysis there is no impact of early 
treatment.
     Analysing the complications and synkinesis,   hemi facial spasm occurred in 2 
cases  in  control  group  and  in  one  patient  in  the  treatment  group.  Synkinesis 
occurred  in  one  case  in  control  group  this  correlated  with  other  author’s 
observation.  But  review  by  quality  standard  subcommittee  of  the  American 
academy of neurology concluded that, none of the studies described a significant 
decrease  in  the  frequency  of  autonomic  synkinesis  (e.g.,  “crocodile  tears”)  in 
patients treated with steroids 34
Complications due to treatment.
            Three studies 54, 56, 57  discussed steroid side effects. Side effects occurred in 
1 to 4% of treated patients. These side effects, in descending order of frequency, 
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are  dyspepsia,  loss  of  blood  sugar  control,  recurrent  duodenal  ulcers,  mood 
swings,  and  acute  psychosis.  The  present  study  observed  treatment  related 
complications in four patients. 
           Two patients who developed dyspepsia were more than 65 years old. The 
patient  who had melena after  therapy was also an alcoholic.  One 47 year  old 
patient treated with steroids and acyclovir developed vomiting. This observation 
indicates that   steroid related complications are more among the older people and 
persons who are having other risk conditions. Otherwise treatment of Bells palsy 
with steroids is effective and safe.
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CONCLUSIONS
• The most reliable prognostic data is obtained after the fourteenth day from 
the onset of palsy.
•  Electrophysiological studies can predict duration of the clinical recovery 
and the outcome of the illness.
• Amplitude ratio of CMAP is the most reliable parameter in assessing the 
prognosis
• Latency  measurement  as  an  independent  factor  is  not  much  helpful  in 
assessing the prognosis, however when combined with the amplitude ratio 
predicts the prognosis.
• Simultaneous  subclinical  facial  nerve  involvement  does  occur  on  the 
contralateral side in 16% of the cases. 
• Bell’s  palsy  patients  with  incomplete  facial  paralysis  have  excellent 
outcomes 
•  Steroids are safe and are probably effective in management of bells palsy 
which improves the rate of recovery.
• Acyclovir in combination with prednisolone is safe and has a definite role 
in improving facial functional outcomes in patients with Bell’s palsy than 
using the drug alone
• Early treatment in cases with incomplete paralysis hastens the recovery and 
it has no effect on cases with severe deficit. 
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PROFORMA
INSTITUTE OF NEUROLOGY
MADRAS MEDICAL COLLEGE. CHENNAI
*********************************************
BELL’S PALSY-PROFORMA
Si no:                                                                                                  Min no:
Name                                                    Age-            Sex               Occupation:
Address:                                                                                        Phone no:
                                                                                  E-mail:
Date of onset                                                          Duration                            Side
 
Symptoms:                                    
                        Ear pain                                            Deviation of angle of mouth
                        Difficulty in closing eyes                Other symptoms
Examination
                        Forehead wrinkling                         Orbicularis occuli
                        Mouth weakness                             Taste
                        Hyperacusis                                    Others
Diease grade:                                                                     Past history
Associated illness:     D.M  /   HT   /PT    
INVESTIGATIONS
                             
 Urine      Alb             Sug             Dep 
 Blood:     Hb             Tc                 Dc                                 ESR:  
    
                  Urea         Sugar            Creatinine
Treatment
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 1) Physiotherapy   
                   
 2) Steroids + Physiotherapy  
                             
 3) Steroids + Acyclovir 
4)  Acyclovir + Physiotherapy
Remarks
 
Follow-up
1) Clinical
Onset 1-Month 2-Months 3-Months 6-Months 12-Months
House brachman
       Grade
2) Electrophysiological evaluation
Visit                          LEFT                       RIGHT
Latency Duration Amplitude Latency Duration Amplitude
3) Complications
Onset 1-Month 2-Months 3-Months 6-Months 12-Months
Hemi-spasms
Synkinesis
Drug related
HOUSE-BRACKMANN---FACIAL NERVE GRADING SYSTEM
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         Grade
                                    Definition
         Gross          Rest                   Motion
Normal           -I  
              
Normal Normal Normal
Mild               -II Slight weakness 
on Close 
inspection  
  
Symmetry + Fore head –Good 
movement.  
Eye-closure with minimal 
effort. 
Mouth –Slight asymmetry
Moderate      -III Obvious Symmetry + Forehead-mild to mod 
movement.
Eye-Closure with maximum 
effort 
Mouth- slight weakness with 
maximum effort. 
Mod to Severe. - 
IV              
Obvious & 
Disfiguring 
Symmetry + Forehead-No movement. 
Eye-Inability to close with 
maximum effort.
Mouth—Asymmetric 
movement with maximum 
effort. 
Severe            - V Only barely 
perceptible 
motion 
Asymmetry Forehead-No movement. 
Eye-Incomplete closure.
Mouth-Only slight 
movement. 
Total              -VI No movement No movement No movement.
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MASTER CHART
CONTROL-Group
Si
No
Age Sex R/L Du Gra
               
                  NCS
Follow-Up
Grade
Ratio 1st 
week
Ratio 2nd 
week
Lat Am
p
Lat Amp
2-4
Wks 
    
4-6
Wks
6-8 
Wks
3
Mon
6
Mon
12
Mon Comp 
 
Drug
side
effec
ts
1 51 M R 7 III A A A A III III II I I I - -
2 56 M R 3 V A A C C V V IV IV IV IV HFS -
3 40 F L 1 IV - - A B IV III III II I I - -
4 37 M R 15 V - - A B V IV IV III II I - -
5 31 F L 13 IV - - A A IV IV III II I I - -
6 30 F L 16 V - - B C V V V IV IV IV - -
7 24
AN
M R 5 IV - - B B IV IV III III II I - -
8 28 F R 11 III - - A B III III III II I I - -
9 41 M L 50 V - - B C V V IV IV IV IV - -
10 40 M L 7 IV A A A A IV III II I I I - -
11 54 M L 7 III - - A B III III II I I I - -
12 37 F L 11 III A A A A III III II I I I - -
13 18 F R 14 V - - C C V IV III III III III - -
14 43 M L 12 V - - B B V IV III III III II HFS -
15 32 M R 22 IV - - A C IV IV III III III III - -
16 18
AN
F R 12 V - - B C V V IV IV III III JW -
17 51 M R 6 IV A A A B IV III III II I I - -
18 31 M L 14 III - - A A III III I I I I - -
19 16 F R 15 IV - - A B IV III III II I I - -
20 38
AN
F L 2 IV A C A B IV III III II I I - -
21 28 M R 10 IV - - A B IV III III III III III - -
22 61 M R 17 IV - - B C IV IV III III III III - -
23 30 F L 11 IV - - A A IV III III II I I - -
90
STEROIDS-Group
Si
No
Age Se
x
R/L Du Gra
               
                  NCS
Follow-Up
Grade
Ratio 1st 
week
Ratio 2nd 
week
Lat Amp Lat Amp
2-4
Wks 
    
4-6
Wks
6-8 
Wks
3
Mon
6
Mon
12
Mon Comp
 
Drug
side
effects
1 16 M R 2 V A A A A IV III II I I I - -
2 37 F L 7 IV - - A A III III I I I I - -
3 28 M L 3 IV A A A A III I I I I I - -
4 19 M R 2 V A B A B V IV III II I I - -
5 65 F R 2 VI A A B C VI VI V IV III III DP -
6 50 F L 3 III - - A A III I I I I I - -
7 37 M L 2 III A B A B III I I I I I - -
8 30 F L 1 IV - - A A IV III II I I I HFS -
9 19 F R 6 VI A B A C VI IV III III III I - -
10 25 M R/L 4 IV - - B A IV II I I I I - -
11 60 M L 2 IV - - A A III II I I I I - -
12 17 M L 2 V - - A A IV III II I I I - -
13 19 F R 3 III A A A A III I I I I I - -
14 22 M L 4 V A A A B IV III II I I I - -
15 34 M L 6 V - - A B IV IV III II I I Mele -
16 33 F R 4 IV - - A A III I I I I I - -
17 17 F R 7 IV A A B C IV IV III III III III - -
18 40 M L 4 IV - - A A III II I I I I - -
19 31 M L 2 III A A A A III I I I I I - -
20 17 F L 1 VI A B B C VI V III III III III - -
21 18 F R 5 V - - A A IV III II I I I - -
22 28 F L 3 IV A A A B IV III III II I I - -
23 30 M R 3 IV A A A B IV III II I I I - -
24 60 M L 6 V A B A C V V V IV IV III DP -
25 50 F R 4 IV - - A A III II I I I I - -
26 37 F L 3 III - - A A III III II I I I - -
27 26 F R 4 IV - - A A III I I I I I - -
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28 30 M L 7 IV A A A C IV IV III III III III - -
29 18 F R 5 V - - A A V IV II I I I - -
30 50 M L 10 IV - - A B IV IV III III III III - -
31 30 F R 1 III A A A A II I I I I I - -
32 47 M L 1 V A A A C IV IV III III II I - -
33 17 M R 2 V - - B C V IV III III III II - -
34 34 F R 9 V - - A B V IV III III II I - -
35 28 F L 2 III - - A A III II I I I I - -
36 13 M R 1 V - - A A V IV III I I I - -
37 44 F R 6 IV A A A B IV III II I I I - -
38 30 F R 4 IV - - A A IV III II I I I - -
39 26 M L 1 IV - - A A IV III I I II I - -
40 19 F R 2 IV - - A A IV III II I I I - -
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STEROIDS + ACYCLOVIR-Group
Si
No
Age Sex R/L Du Gra
               
                  NCS
Follow-Up
Grade
Ratio 1st 
week
Ratio 2nd 
week
Lat Amp Lat Amp
2-4
Wks 
  
4-6
Wks
6-8 
Wks
3
Mon
6
Mon
12
Mon Comp
 
Drug
side
effects
1 3
3
M R 4 IV - - B B IV III II I I I - -
2 3
8
F L 8 V - - A B IV III II I I I - -
3 5
1
M L 7 VI A B B C VI VI V V IV IV - -
4 4
7
F R 1 III A A A A III I I I I I - Vom
5 4
6
F L 5 IV - - A B IV IV III II I I - -
6 2
8
M L 3 V - - A C IV III III II I I - -
7 1
8
M R 1 III A A A A II I I I I I - -
8 3
0
F L 2 IV - - A A III III I I I I - -
9 4
1
M L 10 V A A A A IV III II I I I - -
10 3
7
M R 1 IV - - A B III III I I I I - -
11 3
6
F L 2 V A A A A IV III II I I I - -
12 2
8
F R 7 V - - A A III III II I I I - -
13 3
1
M L 9 IV A B A B IV III III II I I - -
14 1
8
M R 2 III - - A A I I I I I I - -
15 1
7
F R 5 IV - - A A III III II I I I - -
16 3
6
M L 2 III - - A A III II I I I I - -
17 4
0
M R 1 IV - - A A IV III I I I I - -
18 3
7
F L 3 IV - - A B III III II I I I - -
19 3
6
F R 7 V A A A B V IV III II I I - -
20 2
8
M R 3 IV A A A A IV III III II I I - -
21 2
1
M R 2 IV - - A A IV III I I I I - -
22 2
0
M L 2 III - - B A III I I I I I - -
23 2
9
F R 1 V A A A A IV II I I I I - -
24 4
0
M L 3 III - - A A III II I I I I - -
25 6
1
M R 8 V A A A B V IV III III III III - -
26 6
0
M L 7 VI A B A C VI VI V IV IV IV - -
27 3
8
F R 2 IV - - A C IV III III II I I - -
28 1
8
F L 2 IV - - A A IV III II I I I - -
29 2
1
F R 2 IV - - A C IV III III II I I - -
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ACYCLOVIR--Group
Si
No
Age Se
x
R/L Du Gra
               
                  NCS
Follow-Up
Grade
Ratio 1st 
week
Ratio 2nd 
week
Lat Amp Lat Amp
2-4
Wks 
    
4-6
Wks
6-8 
Wks
3
Mon
6
Mon
12
Mon Comp
 
Drug
side
effects
1 51 M R 15 III - - A A III III I I I I - -
2 48 M L 11 V - - B C V V IV IV III III - -
3 47 F R 12 III - - A A III III II I I I - -
4 38 M L 4 V - - A C V V V V V V - -
5 34 M L 3 IV - - A B IV III III II I I - -
6 57 F R 14 IV - - A A IV III III II I I - -
7 43 M L 18 V - - A C V V IV III III III - -
8 30 M R 20 V - - B B V III III II I I - -
9 11 F L 18 V - - A B V IV III II I I - -
10
Key to master chart
                   R / L                     --Side affected, Right or Left                                       Du      ---Duration of illness in days
                   Lat                        --Latency of CMAP                                                   Amp    ---Amplitude ratio of CMAP
                   Wks                    -- Weeks                                                                         Mon    ---Months
                   F                         -- Female                                                                         M        ---Male
                   Comp                 -- Complications                                                              DP      ---Dyspepsia
                   Mele                   -- Melena                                                                         HFS    ---Hemi facial spasm
                   JW                      --Jaw winking                                                                 Vom    ---Vomiting
 
                   A, B, C               --Group as per CMAP, Latency, Amplitude ratio 
                   I, II, III,    }
                   IV, V, VI   }       --Grade as per based on House-Brackmann (HB) system
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